JHS Svendgaard Laboratories Limited has submitted its quarterly compliance report under SEBI regulations, confirming no deviation in the utilization of funds raised through preferential issue for the quarter ended December 31, 2025. The statement was approved by the Board of Directors at their meeting held on February 10, 2026.

Fund Raising Details

The company had raised Rs. 29.99 crores through preferential issue on June 4, 2024. The fund utilization report was filed pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates quarterly disclosure of fund utilization by listed entities.

Fund Allocation and Utilization

The company has modified its original fund allocation objectives, with shareholder approval obtained on July 4, 2024. The revised allocation demonstrates strategic reallocation of resources across different business priorities.

Strategic Reallocation

The most significant change in fund allocation involves the reduction of the original Jammu & Kashmir project allocation from Rs. 2249.99 lakhs to Rs. 599.99 lakhs. This project was initially planned for setting up a new manufacturing facility under the Industrial Development Scheme (IDS) 2021-2030 in Jammu & Kashmir, but has been modified to focus specifically on acquiring equipment for the manufacturing facility.

A new allocation of Rs. 1650.00 lakhs has been created for strategic fund infusion in the group entity JHS Svendgaard Retail Ventures Ltd., aimed at funding expansion plans. Out of this allocation, Rs. 112.50 lakhs has been utilized during the reporting quarter.

Compliance and Oversight

The company reported no comments from the Audit Committee or auditors regarding the fund utilization. The statement confirms that no monitoring agency oversight is applicable for this fund raising. The quarterly report demonstrates the company's adherence to regulatory disclosure requirements and transparent fund management practices.

JHS Svendgaard Laboratories Limited has completed the conversion of warrants into equity shares, marking a significant milestone in its capital restructuring process. The company's Board of Directors approved the allotment of 18,01,801 equity shares on February 01, 2026, following the successful conversion of an equal number of warrants.

Warrant Conversion Details

The conversion involved warrants originally issued on August 03, 2024, at an issue price of Rs. 27.75 per warrant. The Board approved the allotment of equity shares with a face value of Rs. 10.00 each at the same issue price of Rs. 27.75, including a premium of Rs. 17.75 per share.

Allottee Information

Coeus Global Opportunities Fund was the sole beneficiary of this warrant conversion, receiving the entire allocation of 18,01,801 equity shares. The fund paid the balance amount of Rs. 3,74,99,983.31, representing 75% of the total issue price, as required under SEBI regulations.

Impact on Share Capital

Following this allotment, JHS Svendgaard Laboratories' paid-up equity share capital has increased to Rs. 87,40,57,670, now comprising 8,74,05,767 equity shares of Rs. 10.00 face value each. The newly issued shares carry the same rights and privileges as existing equity shares of the company.

Regulatory Compliance

The warrant conversion was conducted in accordance with SEBI (ICDR) Regulations, 2018, and the company has fulfilled all disclosure requirements under Regulation 30 of SEBI Listing Regulations. The Board meeting, which commenced at 10:00 A.M. and concluded at 10:23 A.M., ensured all procedural requirements were met for this preferential allotment on a private placement basis.